Change in Level of Productivity in the Treatment of Schizophrenia With Olanzapine or Other Antipsychotics

BMC Psychiatry - United Kingdom
doi 10.1186/1471-244x-11-87
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cost-Effectiveness Model Comparing Olanzapine and Other Oral Atypical Antipsychotics in the Treatment of Schizophrenia in the United States

Cost Effectiveness and Resource Allocation
Health Policy
2009English

Incidence of Tardive Dyskinesia in Older Adult Patients Treated With Olanzapine or Conventional Antipsychotics

Journal of Geriatric Psychiatry and Neurology
PsychiatryGerontologyGeriatricsMental HealthNeurology
2014English

Antipsychotic Monotherapy and Polypharmacy in the Naturalistic Treatment of Schizophrenia With Atypical Antipsychotics

BMC Psychiatry
PsychiatryMental Health
2005English

The Long-Term Treatment of Schizophrenia With Antipsychotics: A Perennial Debate

World Psychiatry
PsychiatryMental HealthPsychiatric Mental Health
2018English

Aripirazole—Olanzapine Combination for Treatment of Schizophrenia

Canadian Journal of Psychiatry
PsychiatryMental Health
2004English

Treatment Discontinuation of Long-Acting Injectables or Oral Atypical Antipsychotics Among Medicaid Recipients With Schizophrenia

Journal of Medical Economics
Health Policy
2019English

Cost-Effectiveness Analysis of Lurasidone and Olanzapine in the Treatment of Schizophrenia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Cost/Effectiveness of Aripiprazole vs. Olanzapine in the Long-Term Treatment of Schizophrenia

Srpski Arhiv Za Celokupno Lekarstvo
Medicine
2019English

What Is the Role of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia?

Journal of Clinical Psychiatry
MedicinePsychiatryMental Health
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy